These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18534821)

  • 21. Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
    Rosenheck R; Lin H
    J Nerv Ment Dis; 2014 Jan; 202(1):18-24. PubMed ID: 24375207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
    Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
    J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experiences and clinical trials.
    Fusar-Poli RR
    CNS Spectr; 2008 Jun; 13(6):461-2; author reply 462-3. PubMed ID: 18567969
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
    Caroff SN; Davis VG; Miller DD; Davis SM; Rosenheck RA; McEvoy JP; Campbell EC; Saltz BL; Riggio S; Chakos MH; Swartz MS; Keefe RS; Stroup TS; Lieberman JA;
    J Clin Psychiatry; 2011 Mar; 72(3):295-303. PubMed ID: 20816031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
    Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
    BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
    Awad G; Hassan M; Loebel A; Hsu J; Pikalov A; Rajagopalan K
    BMC Psychiatry; 2014 Feb; 14():53. PubMed ID: 24559217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
    Johnsen E; Kroken RA; Wentzel-Larsen T; Jørgensen HA
    BMC Psychiatry; 2010 Mar; 10():26. PubMed ID: 20334680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
    Zhang Y; Wang Q; Reynolds GP; Yue W; Deng W; Yan H; Tan L; Wang C; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Li Y; Yu H; Zhang H; Ma X; Yang F; Li L; Chen Q; Wei W; Zhao L; Wang H; Li X; Guo W; Hu X; Tian Y; Ren H; Ma X; Coid J; Zhang D; Li T;
    J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of phase 3 of the CATIE schizophrenia trial.
    Stroup TS; Lieberman JA; McEvoy JP; Davis SM; Swartz MS; Keefe RS; Miller AL; Rosenheck RA; Hsiao JK;
    Schizophr Res; 2009 Jan; 107(1):1-12. PubMed ID: 19027269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.
    Hermes E; Rosenheck R
    J Psychopharmacol; 2012 Sep; 26(9):1194-200. PubMed ID: 22516668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Did CATIE influence antipsychotic use?
    Citrome L; Jaffe A; Martello D; Allingham B; Levine J
    Psychiatr Serv; 2008 May; 59(5):476. PubMed ID: 18451000
    [No Abstract]   [Full Text] [Related]  

  • 36. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
    Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Reimherr F; Miller DD; McGee M; Khan A; Canive JM; Davis SM; Hsiao JK; Lieberman JA;
    Schizophr Res; 2008 Mar; 100(1-3):39-52. PubMed ID: 18191383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
    Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
    Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
    Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
    Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
    Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
    BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.